

Beaumont

Origination 3/1/2023
Last Approved 3/1/2023
Effective 3/1/2023
Last Revised 3/1/2023
Next Review 2/28/2025

Document Contact Jessica Czinder:
Mgr, Division Laboratory
Area Laboratory-Point of Care
Applicability All Beaumont Hospitals

Point of Care Autoverification Policy

Document Type: Policy

I. PURPOSE AND OBJECTIVE:

- A. The purpose of this document is to provide technical staff with guidelines for autoverification rules between Telcor QML and the Laboratory Information System (LIS). Results in QML autoverify unless a rule is in place to hold the result in a QML exception queue for review. The QML server collects sample results from the Point of Care (POC) interfaced instruments and POC applications (ABL80, ABL90, Hemochron, HemoCue, i-STAT, Liat, Nova StatStrip, Piccolo, MTE (manual test entry), and WebMRE), evaluates results against autoverification rules, and uploads the compiled data to the LIS.
- B. This document is only applicable to areas that are approved for testing under one of the laboratory's Clinical Laboratory Improvement Amendments (CLIA) certificates.

II. POLICY STATEMENT:

- A. This document provides the elements to comply with CAP checklist requirement GEN.43876 Current Autoverification Rules.

III. CLINICAL SIGNIFICANCE:

- A. Autoverification releases results from POC instruments and applications that are within reportable range, have acceptable lipemia, hemolysis and icterus values, do not have instrument flags associated with them, or violate "special" rules.

IV. AUTOVERIFICATION CRITERIA:

- A. When all of the criteria in the Telcor QML Autoverification Rules attachment are met, QML will

automatically send results to the LIS and the QML Result Repository.

- B. Results that do not meet the criteria will be sent to either the QML Results Exceptions or Interface Exceptions queues. These queues are monitored by POC staff and issues are reviewed and resolved on a case-by-case basis.
- C. Quality control (QC) must be completed as indicated by the manufacturer and/or Individualized Quality Control Plan (IQCP) prior to testing patient samples.
 - 1. ABL80, ABL90, CoaguChek, Hemochron, HemoCue, i-STAT, Liat, Nova StatStrip, and Piccolo instruments have QC lock-out that is enabled to restrict instrument access until QC is performed and is acceptable.
 - 2. Manually entered test (manual test entry (MTE) and WebMRE) QC is reviewed by POC staff. If QC is not performed, documented, or repeated, in the event of a QC failure, POC staff follow up with the test area's management team. Patient results will be reviewed during the time period where QC compliance was not met.

V. QUALITY ASSURANCE:

- A. Validation of autoverification is performed initially, before testing is placed in use, annually thereafter, and whenever there is a change to the system that could affect the autoverification logic.
- B. Validation is completed by using patient samples. A patient sample is followed from instrument result to QML to the LIS. All results in all 3 systems must match and follow the rules on the Telcor QML Autoverification Rules attachment. Documentation will be reviewed and approved by any POC staff member.
 - 1. Any applicable calculation verification studies will be performed and reviewed during autoverification performance studies.
 - 2. For Royal Oak staff, please see [Formulas for Manual Calculation - Royal Oak](#) for more information.
- C. Documentation will be saved on the POC SharePoint page for all sites to access.
- D. Any detected failure of the software system will be immediately reviewed in QML by POC staff. Should autoverification need to be suspended at any time, Telcor will be contacted and the instruments affected will be removed from use, if necessary, until the issue is resolved.

VI. REFERENCES:

- A. Lab General Checklist, College of American Pathologists, Northfield, IL, current version.

Attachments

[QML Configuration Detail - Interface Exceptions.pdf](#)

[QML Configuration Detail - Interface Profile - EPIC.pdf](#)

[QML Configuration Summary - Device Flag.pdf](#)

[Telcor QML Autoverification Rules.pdf](#)

Approval Signatures

Step Description	Approver	Date
CLIA Medical Directors	Muhammad Arshad: Physician	3/1/2023
CLIA Medical Directors	Vaishali Pansare: Chief, Pathology	2/10/2023
CLIA Medical Directors	Jeremy Powers: Chief, Pathology	2/8/2023
CLIA Medical Directors	John Pui: Chief, Pathology	2/2/2023
CLIA Medical Directors	Ryan Johnson: OUWB Clinical Faculty	2/2/2023
Policy and Forms Steering Committee Approval (if needed)	Gail Juleff: Project Mgr Policy	2/2/2023
Policy and Forms Steering Committee Approval (if needed)	Jessica Czinder: Mgr, Division Laboratory	1/30/2023
CP System Medical Director	Ann Marie Blenc: System Med Dir, Hematopath	1/27/2023
	Caitlin Schein: Staff Physician	1/26/2023
Technical Director	Nga Yeung Tang: Tech Dir, Clin Chemistry, Path	1/17/2023
POC Best Practices	Jessica Czinder: Mgr, Division Laboratory	1/17/2023
	Jessica Czinder: Mgr, Division Laboratory	1/17/2023

Applicability

Dearborn, Farmington Hills, Grosse Pointe, Royal Oak, Taylor, Trenton, Troy, Wayne